Xencor, Inc. reported $105M of revenue over the trailing twelve months, −29% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $105M (to Q2 2026). Net income: −$163M, trailing twelve months to Q2 2026. Free cash flow: −$208M, trailing twelve months to Q2 2026. Operating margin: −553%, trailing twelve months to Q2 2026.

XNCRXencor, Inc.

Healthcare

$24.63+139% 1Y

$24.63

$10.3252 weeks$29.30

XNCR as reported

Xencor, Inc. reported $105M of revenue over the trailing twelve months, −29% on the year before. 10 reported series are charted on this page, each one as filed.

$105M

Revenue, trailing twelve months · to Q2 2026 · −29% against the twelve months before

Net income: −$163M
Net income · −4.5% year on year · trailing twelve months to Q2 2026
Free cash flow: −$208M
Free cash flow · +54% year on year · trailing twelve months to Q2 2026
Operating margin: −553%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for XNCR, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$105M	−29%	Q2 2026
Net income	−$163M	−4.5%	Q2 2026
EPS	−$2.17	−8.4%	Q2 2026
Operating margin	−553%	n/a	Q2 2026
Net margin	−737%	n/a	Q2 2026
ROE	−25%	n/a	Q2 2026
ROA	−18%	n/a	Q2 2026
ROIC	−23%	n/a	Q2 2026
Free cash flow	−$208M	+54%	Q2 2026
P/E	44.8	n/a	Q3 2022 · 15 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.